WO2012148225A3 - Sustained-release pharmaceutical composition comprising donepezil or pharmaceutically acceptable salt thereof having improved dissolution stability and method for manufacturing the same - Google Patents

Sustained-release pharmaceutical composition comprising donepezil or pharmaceutically acceptable salt thereof having improved dissolution stability and method for manufacturing the same Download PDF

Info

Publication number
WO2012148225A3
WO2012148225A3 PCT/KR2012/003304 KR2012003304W WO2012148225A3 WO 2012148225 A3 WO2012148225 A3 WO 2012148225A3 KR 2012003304 W KR2012003304 W KR 2012003304W WO 2012148225 A3 WO2012148225 A3 WO 2012148225A3
Authority
WO
WIPO (PCT)
Prior art keywords
sustained
donepezil
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
Prior art date
Application number
PCT/KR2012/003304
Other languages
French (fr)
Other versions
WO2012148225A2 (en
Inventor
Sang-Joon Lee
Kwan-Young Chang
Jae-Soon Ahn
Jae-Min Cho
Kyoung-Un Kang
Hyun-Joo Lee
Original Assignee
Bio Pharmartis Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Pharmartis Co., Ltd. filed Critical Bio Pharmartis Co., Ltd.
Publication of WO2012148225A2 publication Critical patent/WO2012148225A2/en
Publication of WO2012148225A3 publication Critical patent/WO2012148225A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a sustained-release formulation comprising donepezil or a pharmaceutically acceptable salt thereof. More particularly, the present invention relates to a sustained-release pharmaceutical composition comprising donepezil or a pharmaceutically acceptable salt thereof, and one or more sustained-release bases selected from the group consisting of polyvinyl acetate and fatty acid ester, and a preparation method thereof.
PCT/KR2012/003304 2011-04-29 2012-04-27 Sustained-release pharmaceutical composition comprising donepezil or pharmaceutically acceptable salt thereof having improved dissolution stability and method for manufacturing the same WO2012148225A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0040791 2011-04-29
KR1020110040791A KR20120122558A (en) 2011-04-29 2011-04-29 Sustained-release pharmaceutical composition comprising donepezil or pharmaceutically acceptable salt thereof having improved dissolution stability and method for manufacturing the same

Publications (2)

Publication Number Publication Date
WO2012148225A2 WO2012148225A2 (en) 2012-11-01
WO2012148225A3 true WO2012148225A3 (en) 2013-01-17

Family

ID=47072947

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/003304 WO2012148225A2 (en) 2011-04-29 2012-04-27 Sustained-release pharmaceutical composition comprising donepezil or pharmaceutically acceptable salt thereof having improved dissolution stability and method for manufacturing the same

Country Status (2)

Country Link
KR (1) KR20120122558A (en)
WO (1) WO2012148225A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101811797B1 (en) * 2013-04-03 2017-12-22 동국제약 주식회사 Pharmaceutical composition comprising donepezil for parenteral administration
CN108078962A (en) * 2018-01-29 2018-05-29 中国药科大学 A kind of instant film of donepezil hydrochloride orally and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050232990A1 (en) * 2003-12-31 2005-10-20 Garth Boehm Donepezil formulations
US20080248107A1 (en) * 2005-08-24 2008-10-09 Rubicon Research Pvt. Ltd. Controlled Release Formulation
US20090053310A1 (en) * 2005-07-01 2009-02-26 Rubicon Research Pvt. Ltd. Novel sustained release dosage form

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050232990A1 (en) * 2003-12-31 2005-10-20 Garth Boehm Donepezil formulations
US20090053310A1 (en) * 2005-07-01 2009-02-26 Rubicon Research Pvt. Ltd. Novel sustained release dosage form
US20080248107A1 (en) * 2005-08-24 2008-10-09 Rubicon Research Pvt. Ltd. Controlled Release Formulation

Also Published As

Publication number Publication date
WO2012148225A2 (en) 2012-11-01
KR20120122558A (en) 2012-11-07

Similar Documents

Publication Publication Date Title
IL254839B (en) Derivatives of piperidine-4- and -2-carboxylic acids, perhydroazepine-4-carboxylic acid and (piperidin-4-yl)-acetic acid and pharmaceutical compositions comprising them
WO2013105101A8 (en) Solid lipid nanoparticles entrapping hydrophilic/ amphiphilic drug and a process for preparing the same
WO2014014835A8 (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
WO2013009142A3 (en) Sustained/release pharmaceutical composition comripising choline alfoscerate or pharmaceutically acceptable salt thereof and method for manufacturing the same
WO2012021715A3 (en) Stable formulations of linaclotide
WO2010114405A3 (en) Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same
WO2012006474A3 (en) Compounds and methods for inhibiting phosphate transport
WO2011157721A3 (en) Ivabradine-containing pharmaceutical composition
WO2012070062A3 (en) Novel polymorph of nilotinib hydrochloride
EP2823819A4 (en) Pharmaceutical composition containing oleanolic acid acetate as an active ingredient for preventing or treating tlr- or il-6-mediated diseases
WO2014207664A3 (en) Stable pharmaceutical composition of asenapine
WO2012101653A3 (en) Modified release pharmaceutical compositions memantine
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
BR112015010271A8 (en) Comicronization product, process for the preparation of a comicronization product, pharmaceutical composition and its uses
WO2013128379A3 (en) Crystalline polymorphic forms of linagliptin
WO2014016754A3 (en) Pharmaceutical compositions of proton pump inhibitor
EP2431361A4 (en) Ascorbic acid aryl acetate/propionate ester, preparation method and pharmaceutical composition thereof
WO2012112841A3 (en) [1,2,4]oxadiazol-3-yl acid salts and crystalline forms and their preparation
WO2011089126A3 (en) Novel retigabine composition
WO2013017910A8 (en) Extended release pharmaceutical compositions containing paliperidone
WO2012148225A3 (en) Sustained-release pharmaceutical composition comprising donepezil or pharmaceutically acceptable salt thereof having improved dissolution stability and method for manufacturing the same
WO2012014052A3 (en) Novel coated extended release pharmaceutical compositions containing paliperidone
EP2722322B8 (en) 1,3-di-oxo-indene derivative, pharmaceutically acceptable salt or optical isomer thereof, preparation method thereof, and pharmaceutical composition containing same as an antiviral, active ingredient
WO2012077968A3 (en) Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12777462

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12777462

Country of ref document: EP

Kind code of ref document: A2